Previous 10 | Next 10 |
2024-03-10 12:23:46 ET Summary AbbVie's full-year results for 2023 might have been weak, but its price is still up by 15% YTD. The disconnect is explained by the revenue dip because of patent expiration for its blockbuster drug Humira, though revenues-ex Humira saw healthy growth....
2024-03-09 13:30:00 ET Summary AbbVie Inc. has demonstrated its ability to overcome headwinds from Humira's loss of exclusivity. AbbVie's Skyrizi and Rinvoq blockbusters have shown remarkable revenue growth, and AbbVie has lifted its long-term outlook. Its recent acquisitions ...
2024-03-09 07:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-09 02:59:00 ET Stocks have been off to a very bullish start in 2024, and investors seem increasingly optimistic about the overall state of the market and the global economy. Now, that's not to say there aren't still notable macroeconomic challenges that are creating a nuanced operat...
2024-03-09 02:27:29 ET Summary AbbVie is a leading pharmaceutical company with a diverse portfolio of products and strong revenue growth. The company has a solid track record of increasing dividends and offers an attractive current yield. Despite the loss of exclusivity on its...
2024-03-08 23:04:54 ET Summary DGRW's dividend growth has been lackluster, but the ETF has provided a superior total return compared against the S&P500. The holdings are weighted more heavily towards tech. As a result, the price is more likely to experience upside. There a...
2024-03-08 17:21:49 ET Summary AbbVie is a pharmaceutical company with a strong history of growth and income generation for investors. The company has a robust pipeline of products in various stages of development, particularly in oncology, immunology, and neuroscience. AbbVie...
2024-03-08 15:00:00 ET More on the markets S&P 500: Time To Hedge, Here's How How The S&P 500 Could Actually Be Closer To 4,200 Than 5,000 SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat ETFs...
2024-03-07 14:13:09 ET More on Cigna Cigna: Trimming The Fat And Staying Focused Cigna: Big Buybacks And Total Return Potential The Cigna Group (CI) Q4 2023 Earnings Call Transcript Cigna in pact with Novo, Eli Lilly to widen obesity coverage Dividend...
AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference PR Newswire NORTH CHICAGO, Ill. , March 7, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays 26th Annual Global Healthcare Conference on Thursday, March 14, 2024 ...
News, Short Squeeze, Breakout and More Instantly...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...
Cantor Fitzgerald has initiated coverage on AbbVie Inc (NYSE:ABBV), a global pharma company. The analyst notes that the company has ...
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week® PR Newswire - AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancin...